Dark

CTMX
CytomX Therapeutics, Inc.
stock NASDAQ

At Close

Aug 5, 2026 3:59:55 PM EDT

3.34USD+0.300%(+0.01)2,029,794

2.82Bid 3.87Ask 1.05Spread

Pre-market

Aug 5, 2026 9:22:30 AM EDT

3.35USD+0.601%(+0.02)1,194

After-hours

Aug 5, 2026 4:58:30 PM EDT

3.35USD+0.299%(+0.01)9,400

OverviewOptionsHistoricalExchangesShortsNews

Jan 20, 2022

08:00AM EST CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire Inc

Jan 19, 2022

08:30AM EST CytomX Announces FDA Clearance Of INDA For CX-904 For Treatment Of Advanced Solid Tumors RTTNews

08:17AM EST CytomX Therapeutics Announces FDA Clearance Of Investigational New Drug Application For CX-904 For Treatment Of Advanced Solid Tumors Benzinga

08:00AM EST CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared the companys Investigational New Drug (IND) application for CX-904, an EGFRxCD3 T-cell-engaging bispecific antibody being co-developed by CytomX and Amgen. GlobeNewswire Inc

Jan 18, 2022

07:22AM EST Barclays Upgrades CytomX Therapeutics to Overweight, Announces $7 Price Target Benzinga

Jan 5, 2022

08:00AM EST CytomX Therapeutics, Inc.(Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th at 3:00 p.m. ET. GlobeNewswire Inc

Dec 22, 2021

06:11AM EST HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11 Benzinga

Dec 21, 2021

02:47PM EST Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Rite Aid Shares Spike Higher Benzinga

12:33PM EST Mid-Day Market Update: Crude Oil Rises 3%; Aldeyra Therapeutics Shares Slide Benzinga

10:12AM EST Mid-Morning Market Update: Markets Open Higher; General Mills Earnings Miss Views Benzinga

08:12AM EST The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail Benzinga

Dec 20, 2021

04:07PM EST UPDATE: CytomX Therapeutics Reports CX-2029 Results Showed 'Objective response rate of 18.8% and disease control rate of 87.5% in unselected advanced squamous non-small cell lung cancer' Benzinga

04:07PM EST CytomX Therapeutics Announces Preliminary Results For Ongoing Phase 2 Expansion Study Of CX-2029, A First-in-Class Antibody-Drug Conjugate Candidate Targeting The Transferrin Receptor, CD71 Benzinga

04:05PM EST -Objective response rate of 18.8 percent and disease control rate of 87.5 percent in unselected advanced squamous non-small cell lung cancer. Enrollment continues- GlobeNewswire Inc

Nov 15, 2021

11:20AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021 Benzinga

10:49AM EST BTIG Initiates Coverage On CytomX Therapeutics with Buy Rating, Announces Price Target of $16 Benzinga

Nov 11, 2021

08:00AM EST CytomX Therapeutics, Inc.(Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in virtual fireside chats at the following investor conferences in November. GlobeNewswire Inc

Nov 5, 2021

09:32AM EDT CytomX Therapeutics Q3 EPS $(0.35) Misses $(0.31) Estimate, Sales $17.59M Miss $18.08M Estimate Benzinga

Nov 4, 2021

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Nov 1, 2021

08:02AM EDT CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Cytokine Platform at Society for Immunotherapy of Cancer Annual Meeting Benzinga

08:00AM EDT CytomX Therapeutics to Present Preclinical Data for Conditionally GlobeNewswire Inc

Oct 28, 2021

08:00AM EDT CytomX Therapeutics to Announce Third Quarter 2021 Financial GlobeNewswire Inc

Oct 18, 2021

08:00AM EDT CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire Inc

Oct 4, 2021

08:00AM EDT CytomX Therapeutics Appoints Dr. Alan Ashworth to Board of Directors GlobeNewswire Inc

Sep 16, 2021

08:00AM EDT CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire Inc

Sep 7, 2021

08:00AM EDT CytomX Therapeutics to Present at H.C. Wainwright 23rd Annual GlobeNewswire Inc

Aug 27, 2021

05:14PM EDT Return on Capital Employed Overview: CytomX Therapeutics Benzinga

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:00AM EDT CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire Inc

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 10, 2021

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

Aug 5, 2021

06:27PM EDT CytomX Therapeutics Files For Mixed-Securities Shelf Offering Of Up To $250M Benzinga

05:48PM EDT CytomX Therapeutics Q2 EPS $(0.30) Beats $(0.32) Estimate, Sales $16.00M Miss $16.86M Estimate Benzinga

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Aug 4, 2021

08:24AM EDT CytomX Therapeutics Announces Multiple Publications On Pacmilimab Benzinga

08:00AM EDT -Translational whole-body PET clinical imaging supports conditional activation in the tumor microenvironment- GlobeNewswire Inc

Aug 2, 2021

08:00AM EDT CytomX Therapeutics to Present at Upcoming August Investor Conferences GlobeNewswire Inc

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 29, 2021

08:00AM EDT CytomX Therapeutics to Announce Second Quarter 2021 Financial GlobeNewswire Inc

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 23, 2021

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

Jul 21, 2021

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 7, 2021

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

Jun 21, 2021

08:02AM EDT CytomX Therapeutics Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research Benzinga

08:00AM EDT CytomX Therapeutics Announces Publication of First-in-Human Data GlobeNewswire Inc

May 28, 2021

10:10AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 28, 2021 Benzinga

06:35AM EDT Barclays Downgrades CytomX Therapeutics to Underweight, Lowers Price Target to $7 Benzinga

May 27, 2021

08:00AM EDT CytomX Therapeutics to Present at Jefferies Virtual Healthcare GlobeNewswire Inc

May 6, 2021

05:34PM EDT CytomX Therapeutics Q1 EPS $(0.26) Beats $(0.35) Estimate, Sales $15.97M Beat $15.43M Estimate Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

Apr 29, 2021

08:00AM EDT CytomX Therapeutics to Announce First Quarter 2021 Financial GlobeNewswire Inc

Apr 14, 2021

04:01PM EDT CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire Inc

Apr 7, 2021

10:07AM EDT CytomX Therapeutics Shares Down 1.1% Ahead Of Virtual Investor Event Starting 1 p.m. EDT Benzinga

Mar 29, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2021 Benzinga

07:36AM EDT JP Morgan Initiates Coverage On CytomX Therapeutics with Overweight Rating, Announces Price Target of $14 Benzinga

Mar 24, 2021

08:00AM EDT CytomX Therapeutics, Inc.(Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody technology platform, today announced that it will host a virtual investor event at 1:00 p.m. 3:00 p.m. ET / 10:00 a.m. 12:00 p.m. PT on Wednesday, April 7, 2021. GlobeNewswire Inc

Mar 23, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2021 Benzinga

07:30AM EDT Jefferies Upgrades CytomX Therapeutics to Buy Benzinga

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

Feb 24, 2021

04:49PM EST CytomX Therapeutics Q4 EPS $(0.71) Misses $(0.50) Estimate, Sales $16.40M Beat $15.41M Estimate Benzinga

04:15PM EST CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 GlobeNewswire Inc

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

03:35AM EST Earnings Scheduled For February 24, 2021 Benzinga

Feb 23, 2021

10:26AM EST A Preview Of CytomX Therapeutics's Earnings Benzinga

Feb 22, 2021

08:00AM EST CytomX Therapeutics to Present at Upcoming March Virtual Investor GlobeNewswire Inc

Feb 19, 2021

08:00AM EST CytomX Therapeutics Announces New Employment Inducement Grant GlobeNewswire Inc

Feb 17, 2021

08:00AM EST CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 GlobeNewswire Inc

Feb 4, 2021

08:00AM EST CytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 GlobeNewswire Inc

Feb 3, 2021

08:19AM EST UPDATE - CytomX Therapeutics Announces Full Exercise of GlobeNewswire Inc

08:00AM EST CytomX Therapeutics Announces Full Exercise of GlobeNewswire Inc

Jan 26, 2021

05:24PM EST Point72 Asset Management LP Reports In 13G Filing A 9.1% Passive Stake In CytomX Therapeutics Benzinga

08:00AM EST CytomX Therapeutics Announces Closing of Public Offering of Common GlobeNewswire Inc

Jan 21, 2021

02:46PM EST Mid-Day Market Update: Nasdaq Rises Over 50 Points; Dyne Therapeutics Shares Plummet Benzinga

02:46PM EST Mid-Afternoon Market Update: Dow Rises 50 Points; Vinco Ventures Shares Spike Higher Benzinga

12:07PM EST Mid-Day Market Update: Nasdaq Rises Over 50 Points; Dyne Therapeutics Shares Plummet Benzinga

05:39AM EST CytomX Therapeutics Priced 14,285,714 Share Public Offering of Common Stock @$7/Share Benzinga

Jan 20, 2021

09:56PM EST CytomX Therapeutics Prices Underwritten Public Offering Of 14.29 Mln Shares At $7.00/shr RTTNews

09:50PM EST CytomX Therapeutics Announces Pricing of $100 Million Public GlobeNewswire Inc

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 19, 2021

08:17PM EST CytomX Therapeutics Commences Underwritten Public Offering Of $75.0 Mln Of Common Stock RTTNews

04:35PM EST CytomX Therapeutics Announces Proposed $75M Common Stock Offering Benzinga

04:35PM EST CytomX Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

08:00AM EST CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire Inc

Jan 7, 2021

08:00AM EST CytomX Therapeutics to Present at the 39th Annual J.P. Morgan GlobeNewswire Inc

Dec 22, 2020

04:05PM EST CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors GlobeNewswire Inc

Dec 3, 2020

08:00AM EST CytomX Therapeutics to Present Updates on CX-2009 at 2020 San GlobeNewswire Inc

Nov 11, 2020

04:01PM EST CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual healthcare conferences in November. GlobeNewswire Inc

Nov 5, 2020

05:39PM EST CytomX Therapeutics Q3 EPS $(0.32) Beats $(0.48) Estimate, Sales $17.80M Beat $16.34M Estimate Benzinga

08:05AM EST CytomX Therapeutics Reports Treatment Of First Patient In Phase 2 Expansion Study Of CX-2029 Benzinga

08:02AM EST CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 29, 2020

08:00AM EDT CytomX Therapeutics to Announce Third Quarter 2020 Financial Results GlobeNewswire Inc

Oct 6, 2020

04:11PM EDT CytomX Therapeutics Announces Planned Retirement Of Chief Scientific Officer Benzinga

04:10PM EDT Marcia P. Belvin, Ph.D., Promoted to Senior Vice President, Head of Research GlobeNewswire Inc

Sep 22, 2020

09:36AM EDT Benzinga's Top Upgrades, Downgrades For September 22, 2020 Benzinga

07:11AM EDT Guggenheim Downgrades CytomX Therapeutics to Neutral Benzinga

Sep 18, 2020

08:00AM EDT CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire Inc

Sep 2, 2020

08:00AM EDT CytomX Therapeutics to Participate in Upcoming Healthcare Conferences GlobeNewswire Inc

Aug 6, 2020

05:40PM EDT CytomX Therapeutics Q2 EPS $(0.34) Up From $(0.64) YoY, Sales $16.61M Up From $9.01M YoY Benzinga

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

Aug 4, 2020

08:01AM EDT CytomX Therapeutics to Participate in the 2020 Wedbush PacGrow GlobeNewswire Inc

Jul 28, 2020

08:01AM EDT CytomX Therapeutics to Announce Second Quarter 2020 Financial Results GlobeNewswire Inc

Jul 17, 2020

01:00PM EDT CTMX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds GlobeNewswire Inc

11:21AM EDT Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) between May 17, 2018, and May 13, 2020, inclusive (the Class Period), of the important July 20, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for CytomX investors under the federal securities laws. GlobeNewswire Inc

Jul 16, 2020

08:00AM EDT The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of CytomX Therapeutics, Inc. investors (NASDAQ: CTMX) (CytomX or the Company) that acquired CytomX securities betweenMay 17, 2018, and May 13, 2020. GlobeNewswire Inc

Jul 14, 2020

11:00AM EDT CTMX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against CytomX Therapeutics, Inc. and Lead Plaintiff Deadline: July 20, 2020 Business Wire

Jul 12, 2020

11:00AM EDT The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of CytomX Therapeutics, Inc. investors (NASDAQ: CTMX) (CytomX or the Company) that acquired CytomX securities betweenMay 17, 2018, and May 13, 2020. GlobeNewswire Inc